Shots:
- Pfizer & Chai Discovery have entered into a licensing agreement, allowing Pfizer to integrate Chai’s AI-driven drug discovery platform into its biologics research workflows
- As per the deal, Pfizer will integrate Chai’s AI platform into its drug discovery engine, gaining early access to the Chai-3 model & a customized AI model built using Pfizer’s proprietary data & tailored to its research workflows
- Chai-3 is designed to improve AI-driven antibody discovery, supporting the development of therapeutic antibodies, multispecific molecules, & candidates against hard-to-drug targets, while enhancing design success rates & generalizability
Ref: Businesswire | Image: Chai & Pfizer | Press Release
Related News: Pfizer and Innovent Biologics Partner to Accelerate 12 Oncology Programs in a Deal Valued at ~$10.5B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
